Prolactin receptor attenuation induces zinc pool redistribution through ZnT2 and decreases invasion in MDA-MB-453 breast cancer cells

Experimental Cell Research

Volumn 321, Issue 2, 2014, Pages 190-200

  Bostanci, Zeynep ^a,b   Alam, Samina ^a,b   Soybel, David I ^a,b,c   Kelleher, Shannon L ^a,b,c  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^c PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Breast cancer; Lysosomes; Mitochondria; MMP 2; PRL R; ZnT2

Indexed keywords

CALNEXIN; ESTROGEN RECEPTOR; GELATINASE A; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MESSENGER RNA; METALLOTHIONEIN; PROLACTIN RECEPTOR; SMALL INTERFERING RNA; ZINC;

ARTICLE; ATTENUATION; BREAST CANCER; CANCER CELL; CELL FUNCTION; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; LYSOSOME; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; PRIORITY JOURNAL; TUMOR INVASION; ZINC METABOLISM;

BREAST CANCER; LYSOSOMES; MITOCHONDRIA; MMP-2; PRL-R; ZNT2;

BIOLOGICAL TRANSPORT; BREAST NEOPLASMS; CATION TRANSPORT PROTEINS; FEMALE; HORMONE ANTAGONISTS; HUMANS; MITOCHONDRIA; NEOPLASM INVASIVENESS; OXIDATION-REDUCTION; RECEPTORS, PROLACTIN; RNA, SMALL INTERFERING; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED; ZINC;

EID: 84895065690     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2013.12.005     Document Type: Article

References (61)

1. Cancer Facts & Figures 2013, [Online]. Available:. [Accessed: 20-May-2013]. http://www.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2013.
2. J. Ferlay, H. Shin, F. Bray, D. Forman, C. Mathers, D. Parkin, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon (France), (2010). [Online]. Available:. [Accessed: 18-Jul-2012]. http://globocan.iarc.fr.
3. Pearson O.H., Llerena O., Llerena L., Molina A., Butler T. Prolactin-dependent rat mammary cancer: a model for man?. Trans. Assoc. Am. Physicians 1969, 82:225-238.
4. Welsch C.W., Nagasawa H. Prolactin and murine mammary tumorigenesis: a review. Cancer Res. 1977, 37:951-963.
5. Tworoger S.S., Eliassen A.H., Sluss P., Hankinson S.E. A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2007, 25:1482-1488.
6. Gadd S.L., Clevenger C.V. Ligand-independent dimerization of the human prolactin receptor isoforms: functional implications. Mol. Endocrinol. (Baltimore, Md.) 2006, 20:2734-2746.
7. Sultan A.S., Brim H., Sherif Z.A. Co-overexpression of Janus kinase 2 and signal transducer and activator of transcription 5a promotes differentiation of mammary cancer cells through reversal of epithelial-mesenchymal transition. Cancer Sci 2008, 99:272-279.
8. Das R., Vonderhaar B.K. Activation of raf-1, MEK, and MAP kinase in prolactin responsive mammary cells. Breast Cancer Res. Treat 1996, 40:141-149.
9. Miller S.L., Antico G., Raghunath P.N., Tomaszewski J.E., Clevenger C.V. Nek3 kinase regulates prolactin-mediated cytoskeletal reorganization and motility of breast cancer cells. Oncogene 2007, 26:4668-4678.
10. Binart N., Imbert-Bollore P., Baran N., Viglietta C., Kelly P.A. A short form of the prolactin (PRL) receptor is able to rescue mammopoiesis in heterozygous PRL receptor mice. Mol. Endocrinol. (Baltimore, Md.) 2003, 17:1066-1074.
11. Qazi A.M., Tsai-Morris C.-H., Dufau M.L. Ligand-independent homo- and heterodimerization of human prolactin receptor variants: inhibitory action of the short forms by heterodimerization. Mol. Endocrinol. (Baltimore, Md.) 2006, 20:1912-1923.
12. Tan D., Walker A.M. Short form 1b human prolactin receptor down-regulates expression of the long form. J. Mol. Endocrinol 2010, 44:187-194.
13. Wang P.S., Walker A.M., Tsuang M.T., Orav E.J., Glynn R.J., Levin R., et al. Dopamine antagonists and the development of breast cancer. Arch. Gen. Psychiatry 2002, 59:1147-1154.
14. Rose-Hellekant T.A., Arendt L.M., Schroeder M.D., Gilchrist K., Sandgren E.P., Schuler L.A. Prolactin induces ERalpha-positive and ERalpha-negative mammary cancer in transgenic mice. Oncogene 2003, 22:4664-4674.
15. Tomblyn S., Langenheim J.F., Jacquemart I.C., Holle E., Chen W.Y. The role of human prolactin and its antagonist, G129R, in mammary gland development and DMBA-initiated tumorigenesis in transgenic mice. Int. J. Oncol. 2005, 27:1381-1389.
16. Arendt L.M., Grafwallner-Huseth T.L., Schuler L.A. Prolactin-growth factor crosstalk reduces mammary estrogen responsiveness despite elevated ERalpha expression. Am. J. Pathol. 2009, 174:1065-1074.
17. Fisher B., Redmond C., Fisher E.R., Caplan R. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol 1988, 6:1076-1087.
18. Wu A.M.L., Dalvi P., Lu X., Yang M., Riddick D.S., Matthews J., et al. Induction of multidrug resistance transporter ABCG2 by prolactin in human breast cancer cells. Mol. Pharmacol. 2013, 83:377-388.
19. LaPensee E.W., Schwemberger S.J., LaPensee C.R., Bahassi E.M., Afton S.E., Ben-Jonathan N. Prolactin confers resistance against cisplatin in breast cancer cells by activating glutathione-S-transferase. Carcinogenesis 2009, 30:1298-1304.
20. Reynolds C., Montone K.T., Powell C.M., Tomaszewski J.E., Clevenger C.V. Expression of prolactin and its receptor in human breast carcinoma. Endocrinology 1997, 138:5555-5560.
21. Peirce S.K., Chen W.Y., Chen W.Y. Quantification of prolactin receptor mRNA in multiple human tissues and cancer cell lines by real time RT-PCR. J. Endocrinol 2001, 171:R1-R4.
22. Frontini L., Lissoni P., Vaghi M., Perego M.S., Pescia S., Ardizzoia A., et al. Enhancement of the efficacy of weekly low-dose taxotere by the long acting anti-prolactinemic drug cabergoline in pretreated metastatic breast cancer. Anticancer Res 2004, 24:4223-4226.
23. Damiano J.S., Rendahl K.G., Karim C., Embry M.G., Ghoddusi M., Holash J., et al. Neutralization of prolactin receptor function by monoclonal antibody LFA102, a novel potential therapeutic for the treatment of breast cancer. Mol. Cancer Ther. 2013, 12:295-305.
24. Ramamoorthy P., Sticca R., Wagner T.E., Chen W.Y. In vitro studies of a prolactin antagonist, hPRL-G129R in human breast cancer cells. Int. J. Oncol. 2001, 18:25-32.
25. Howell S.J., Anderson E., Hunter T., Farnie G., Clarke R.B. Prolactin receptor antagonism reduces the clonogenic capacity of breast cancer cells and potentiates doxorubicin and paclitaxel cytotoxicity. Breast Cancer Res. BCR 2008, 10:R68.
26. Chen W.Y., Ramamoorthy P., Chen N., Sticca R., Wagner T.E. A human prolactin antagonist, hPRL-G129R, inhibits breast cancer cell proliferation through induction of apoptosis. Clin. Cancer Res. 1999, 5:3583-3593.
27. Scotti M.L., Langenheim J.F., Tomblyn S., Springs A.E.B., Chen W.Y. Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells. Breast Cancer Res. Treat. 2008, 111:241-250.
28. Qian L., Lopez V., Seo Y.A., Kelleher S.L. Prolactin regulates ZNT2 expression through the JAK2/STAT5 signaling pathway in mammary cells. Am. J. Physiol. Cell Physiol 2009, 297:C369-C377.
29. Kelleher S.L., Lönnerdal B. Zip3 plays a major role in zinc uptake into mammary epithelial cells and is regulated by prolactin. Am. J. Physiol. Cell Physiol 2005, 288:C1042-C1047.
30. Lopez V., Kelleher S.L. Zinc transporter-2 (ZnT2) variants are localized to distinct subcellular compartments and functionally transport zinc. Biochem. J 2009, 422:43-52.
31. Palmiter R.D., Cole T.B., Findley S.D. ZnT-2, a mammalian protein that confers resistance to zinc by facilitating vesicular sequestration. EMBO J 1996, 15:1784-1791.
32. Seo Y.A., Lopez V., Kelleher S.L. A histidine-rich motif mediates mitochondrial localization of ZnT2 to modulate mitochondrial function. Am. J. Physiol.-Cell Physiol 2011, 300:C1479-C1489.
33. McCormick N., Velasquez V., Finney L., Vogt S., Kelleher S.L. X-Ray fluorescence microscopy reveals accumulation and secretion of discrete intracellular zinc pools in the lactating mouse mammary gland. PLoS One 2010, 5.
34. Andrews G.K. Regulation of metallothionein gene expression by oxidative stress and metal ions. Biochem. Pharmacol 2000, 59:95-104.
35. Van Wart H.E., Birkedal-Hansen H. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc. Nat. Acad. Sci. U.S.A. 1990, 87:5578-5582.
36. Shian S.-G., Kao Y.-R., Wu F.Y.-H., Wu C.-W. Inhibition of invasion and angiogenesis by zinc-chelating agent disulfiram. Mol. Pharmacol. 2003, 64:1076-1084.
37. Clevenger C.V., Zheng J., Jablonski E.M., Galbaugh T.L., Fang F. From bench to bedside: future potential for the translation of prolactin inhibitors as breast cancer therapeutics. J. Mammary Gland Biol. Neoplasia 2008, 13:147-156.
38. Falcón-Pérez J.M., Dell'Angelica E.C. Zinc transporter 2 (SLC30A2) can suppress the vesicular zinc defect of adaptor protein 3-depleted fibroblasts by promoting zinc accumulation in lysosomes. Exp. Cell Res 2007, 313:1473-1483.
39. Wei Q., He W., Yao J., Guo L., Lu Y., Cao X. Identification and characterization of microRNAs expressed in human breast cancer T-47D cells in response to prolactin treatment by Solexa deep-sequencing technology. Biochem. Biophys. Res. Commun 2013, 432:480-487.
40. Ouzounova M., Vuong T., Ancey P.-B., Ferrand M., Durand G., Kelm F.Le-Calvez, et al. MicroRNA miR-30 family regulates non-attachment growth of breast cancer cells. BMC Genomics 2013, 14:139.
41. MicroRNA.org Targets and Expression, [Online]. Available:. [Accessed: 21-Jun-2013]. http://www.microrna.org/microrna/getMrna.do?gene=7780&utr=22874&organism=9606.
42. Tan Y.-F., O'Toole N., Taylor N.L., Millar A.H. Divalent metal ions in plant mitochondria and their role in interactions with proteins and oxidative stress-induced damage to respiratory function. Plant Physiol 2010, 152:747-761.
43. Ray P.D., Huang B.-W., Tsuji Y. Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell Signal. 2012, 24:981-990.
44. Peirce S.K., Chen W.Y. Human prolactin and its antagonist, hPRL-G129R, regulate bax and bcl-2 gene expression in human breast cancer cells and transgenic mice. Oncogene 2004, 23:1248-1255.
45. Bernhard D., Schwaiger W., Crazzolara R., Tinhofer I., Kofler R., Csordas A. Enhanced MTT-reducing activity under growth inhibition by resveratrol in CEM-C7H2 lymphocytic leukemia cells. Cancer Lett 2003, 195:193-199.
46. Vallon R., Müller R., Moosmayer D., Gerlach E., Angel P. The catalytic domain of activated collagenase I (MMP-1) is absolutely required for interaction with its specific inhibitor, tissue inhibitor of metalloproteinases-1 (TIMP-1). Eur. J. Biochem. FEBS 1997, 244:81-88.
47. Pourmotabbed T., Aelion J.A., Tyrrell D., Hasty K.A., Bu C.H., Mainardi C.L. Role of the conserved histidine and aspartic acid residues in activity and stabilization of human gelatinase B: an example of matrix metalloproteinases. J. Protein Chem. 1995, 14:527-535.
48. Agrawal A., Romero-Perez D., Jacobsen J.A., Villarreal F.J., Cohen S.M. Zinc-binding groups modulate selective inhibition of MMPs. ChemMedChem 2008, 3:812-820.
49. Newsome A.L., Johnson J.P., Seipelt R.L., Thompson M.W. Apolactoferrin inhibits the catalytic domain of matrix metalloproteinase-2 by zinc chelation. Biochem. Cell Biol. Biochim. Biol. Cell. 2007, 85:563-572.
50. Sbai O., Ould-Yahoui A., Ferhat L., Gueye Y., Bernard A., Charrat E., et al. Differential vesicular distribution and trafficking of MMP-2, MMP-9, and their inhibitors in astrocytes. Glia 2010, 58:344-366.
51. Borovanský J., Riley P.A. Cytotoxicity of zinc in vitro. Chem. Biol. Interact. 1989, 69:279-291.
52. Bastow M., Kriedt C.L., Baldassare J., Shah M., Klein C. Zinc is a potential therapeutic for chemoresistant ovarian cancer. J. Exp. Ther. Oncol 2011, 9:175-181.
53. Uzzo R.G., Leavis P., Hatch W., Gabai V.L., Dulin N., Zvartau N., et al. Zinc inhibits nuclear factor-kappa B activation and sensitizes prostate cancer cells to cytotoxic agents. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2002, 8:3579-3583.
54. Hwang J.J., Kim H.N., Kim J., Cho D.-H., Kim M.J., Kim Y.-S., et al. Zinc(II) ion mediates tamoxifen-induced autophagy and cell death in MCF-7 breast cancer cell line. Biometals Int. J. Role Met. Ions Biol. Biochem. Med. 2010, 23:997-1013.
55. Tominaga H., Kodama S., Matsuda N., Suzuki K., Watanabe M. Involvement of reactive oxygen species (ROS) in the induction of genetic instability by radiation. J. Radiat. Res. (Tokyo) 2004, 45:181-188.
56. Lopez V., Kelleher S.L. Zip6-attenuation promotes epithelial-to-mesenchymal transition in ductal breast tumor (T47D) cells. Exp. Cell Res 2010, 316:366-375.
57. Chowanadisai W., Lönnerdal B., Kelleher S.L. Identification of a mutation in SLC30A2 (ZnT-2) in women with low milk zinc concentration that results in transient neonatal zinc deficiency. J. Biol. Chem 2006, 281:39699-39707.
58. Galsgaard E.D., Rasmussen B.B., Folkesson C.G., Rasmussen L.M., Berchtold M.W., Christensen L., et al. Re-evaluation of the prolactin receptor expression in human breast cancer. J. Endocrinol. 2009, 201:115-128.
59. Kelleher S.L., Lönnerdal B. Zinc transporters in the rat mammary gland respond to marginal zinc and vitamin A intakes during lactation. J. Nutr 2002, 132:3280-3285.
60. Muylle F., Adriaensen D., De Coen W., Timmermans J.-P., Blust R. Tracing of labile zinc in live fish hepatocytes using FluoZin-3. BioMetals 2006, 19:437-450.
61. Lopez V., Foolad F., Kelleher S.L. ZnT2-overexpression represses the cytotoxic effects of zinc hyper-accumulation in malignant metallothionein-null T47D breast tumor cells. Cancer Lett 2011, 304:41-51.